103203-83-4

Basic information

• Product Name: 3-ALLYLOXY-BENZOIC ACID
• Synonyms: 3-ALLYLOXY-BENZOIC ACID;TIMTEC-BB SBB010624;ZERENEX E/5016819;3-(allyloxy)benzoic acid(SALTDATA: 0.13H2O);3-(Allyloxy)benzoic acid AldrichCPR;Benzoic acid, 3-(2-propenyloxy)-
• CAS NO: 103203-83-4
• Molecular Formula: C₁₀H₁₀O₃
• Molecular Weight: 178.18
• Mol File: 103203-83-4.mol

Chemical Properties

• Boiling Point: 329.4°C at 760 mmHg
• Flash Point: 132.4°C
• Appearance: /
• Density: 1.156g/cm³
• Vapor Pressure: 7.13E-05mmHg at 25°C
• Refractive Index: 1.546
• CAS DataBase Reference: 3-ALLYLOXY-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ALLYLOXY-BENZOIC ACID(103203-83-4)
• EPA Substance Registry System: 3-ALLYLOXY-BENZOIC ACID(103203-83-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 103203-83-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Allyloxy-benzoic acid is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medications.
Used in Organic Compounds Synthesis:
3-ALLYLOXY-BENZOIC ACID is also employed in the synthesis of organic compounds, playing a crucial role in the creation of various chemical products.
Used as a Reagent in Organic Chemical Production:
3-Allyloxy-benzoic acid serves as a reagent in the production of a range of organic chemicals, facilitating various chemical reactions and processes.
Used in Anti-Inflammatory Applications:
3-Allyloxy-benzoic acid has been studied for its potential anti-inflammatory properties, suggesting a possible use in the development of treatments for inflammatory conditions.
Used in Antioxidant Applications:
3-ALLYLOXY-BENZOIC ACID has also been investigated for its antioxidant properties, indicating its potential use in formulations that combat oxidative stress and related conditions.
Used in Drug Delivery Applications:
3-Allyloxy-benzoic acid is being explored for its use in the development of novel materials for drug delivery applications, potentially enhancing the efficacy and targeted delivery of therapeutic agents.

InChI:InChI=1/C10H10O3/c1-2-6-13-9-5-3-4-8(7-9)10(11)12/h2-5,7H,1,6H2,(H,11,12)

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 106-95-6 allyl bromide 
• 99-06-9 3-Carboxyphenol 
• 79250-46-7 methyl 3-(prop-2-enyloxy)benzoate 
• 105208-23-9 ethyl 4-(allyloxy)benzoate 
• 26505-19-1 allyl 3-allyloxybenzoate 
• 185112-19-0 (R)-(3-Allyloxy-phenyl)-azido-acetic acid 
• 185112-18-9 (2R,4R)-3-<2-azido-2-<3-(allyloxy)phenyl>-1-oxoethyl>-4-(phenylmethyl)-2-oxazolidinone 

Downstream Products

• 1290053-77-8 1-(3-(4-(3-(aminomethyl)phenyl)piperidine-1-carbonyl)phenoxy)-3-hydroxypropan-2-one 
• 1290056-62-0 tert-butyl 3-(1-(3-(2,3-dihydroxypropoxy)benzoyl)piperidin-4-yl)benzylcarbamate 
• 1290056-63-1 tert-butyl 3-(1-(3-(3-((tert-butyldimethylsilyl)oxy)-2-hydroxypropoxy)benzoyl)piperidin-4-yl)benzylcarbamate 
• 1290056-64-2 tert-butyl 3-(1-(3-(3-((tert-butyldimethylsilyl)oxy)-2-oxopropoxy)benzoyl)piperidin-4-yl)benzylcarbamate 
• 1290056-61-9 tert-butyl 3-(1-(3-(allyloxy)benzoyl)piperidin-4-yl)benzylcarbamate 
• 79250-46-7 methyl 3-(prop-2-enyloxy)benzoate 

Relevant articles and documents

Sulfoximine-Assisted One-Pot Unsymmetrical Multiple Annulation of Arenes: A Combined Experimental and Computational Study

Discussed herein is an unprecedented Ru-catalyzed one-pot unsymmetrical C-H difunctionalization of arenes comprising intramolecular hydroarylation of olefins and intermolecular annulation of alkynes. This unprecedented 2-fold C-H functionalization is validated on the basis of experimental and density functional theory (DFT) study. The transformation readily occurs with the assistance of methylphenyl sulfoximine (MPS) directing group in the presence of Ru catalyst forming two C-C and one C-N bonds in a single operation. The overall process is atom economical and step-efficient and provides unusual dihydrofuran-fused isoquinolone heterocycles. Further annulation of NH and the proximal o-C-H-arene of isoquinolone with alkynes build highly conjugated novel polycyclic compounds. Overall, three independent annulations in arene motifs are visualized and thoughtfully executed; finally, 5 ring-fused structural entities are constructed forming three C-C and two C-N bonds.

Truncated Itraconazole Analogues Exhibiting Potent Anti-Hedgehog Activity and Improved Drug-like Properties

We conducted a structure-activity relationship study to explore simplified analogues of the itraconazole (ITZ) scaffold for their ability to inhibit the hedgehog (Hh) signaling pathway. These analogues were based on exploring the effects of chemical modifications to the linker and triazolone/side chain region of ITZ. Analogue 11 was identified as the most potent compound in our first generation, with an IC50 value of 81 nM in a murine Hh-dependent basal cell carcinoma. Metabolic identification studies led us to identify truncated piperazine (26) as the major metabolite in human liver microsomes (HLMs) and an improved Hh pathway inhibitor (IC50 = 22 nM). This work verifies that continued truncation of the ITZ scaffold is a practical method to maintain potent anti-Hh activity while also reducing the molecular weight for the ITZ scaffold and achieving improved pharmacokinetic properties.

TRUNCATED ITRACONAZOLE ANALOGUES AND METHODS OF USE THEREOF

Disclosed herein are analogues of itraconazole that are potent hedgehog signaling pathway inhibitors. The compounds are expected to be useful in the treatment of cell proliferation disorders such as cancer, particularly cancers that are dependent upon the hedgehog signaling pathway such as basal cell carcinoma and medulloblastoma.

Rhodium-Catalyzed Twofold Unsymmetrical C-H Alkenylation-Annulation/Thiolation Reaction to Access Thiobenzofurans

A Rh(III)-catalyzed twofold unsymmetrical C-H alkenylation-annulation/thiolation reaction has been developed, enabling the straightforward and efficient synthesis of various thiobenzofurans in one step. This robust protocol proceeds with a broad substrate scope and good functional group tolerance under relatively mild reaction conditions.

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).

Ruthenium-Catalyzed Hydroarylation and One-Pot Twofold Unsymmetrical C?H Functionalization of Arenes

A methyl phenyl sulfoximine (MPS) is used as a directing group in the ruthenium-catalyzed intramolecular hydroarylation of alkene-tethered benzoic acid derivatives to afford dihydrobenzofurans and indolines in good to excellent yields. A one-pot, unsymmetrical, twofold C?H functionalization involving intramolecular C?C and intermolecular C?C/C?N bond formations is successfully demonstrated by using a single set of catalytic reaction conditions, which is unprecedented thus far. A novel isoquinolone-bearing dihydrobenzofuran is constructed through an unsymmetrical twofold C?H functionalization.

ARYL SULFONOHYDRAZIDES

Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing C6 heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, CI, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 aIkyI and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.

Small macrocycles as highly active integrin α2β1 antagonists

Starting from clinical candidates Firategrast, Valategrast, and AJM-300, a series of novel macrocyclic platelet collagen receptor α2β1 antagonists were developed. The amino acid derived low molecular weight 14-18-membered macrocycles turned out to be highly active toward integrin α2β1 with IC50s in the low nanomolar range. The conformation of the macrocycles was found to be highly important for the activity, and an X-ray crystal structure was obtained to clarify this. Subsequent docking into the metal-ion-dependent adhesion site (MIDAS) of a β1 unit revealed a binding model indicating key binding features. Macrocycle 38 was selected for further in vitro and in vivo profiling.

Rh(iii)-Catalyzed intramolecular redox-neutral cyclization of alkenes via C-H activation

Biologically interesting fused oligocyclic lactams have been prepared via an intramolecular redox-neutral cyclization process. By the proper choice of the substrates with a wide variety of tethered olefins, the less favored C-H bond can be activated and f

COFERONS AND METHODS OF MAKING AND USING THEM

The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.